Vertebral, Subclavian, Brachiocephalic, and Unusual Carotid/Cervical Arterial Conditions
Vertebral, subclavian, brachiocephalic, and uncommon cervical arterial conditions kept separate from the carotid stenosis template. The chapter frames mechanism, evidence base, and threshold for intervention for posterior-circulation disease, subclavian steal, cervical dissection, and large-vessel vasculitis.
Consult corner: A bedside consult-style discussion focused on what the clinician should decide next and what not to overinterpret.
General medical education, not patient-specific advice.
Choose the hostsDefinition and presentation
Non-carotid supra-aortic and cervical arterial diseases represent distinct clinical entities with unique ischemic mechanisms, anatomical presentations, and management thresholds. They are not managed as direct extensions of carotid bifurcation disease .
Clinical presentation depends on the specific arterial territory and underlying pathology:
- Vertebral artery stenosis presents with posterior-circulation ischemia.
- Subclavian artery stenosis or occlusion presents with upper-extremity claudication, coronary-subclavian steal in patients with a prior left internal mammary artery bypass, or vertebrobasilar steal symptoms.
- Brachiocephalic (innominate) artery disease presents with combined or isolated cerebral and upper-extremity ischemia.
- Cervical artery dissection presents acutely as stroke or local symptoms, classified by anatomic location and bleeding context (extracranial ischemic, intracranial nonhemorrhagic, or intracranial with hemorrhage).
- Large-vessel vasculitis (giant cell arteritis and Takayasu arteritis) presents as a systemic inflammatory disease with secondary cervical or supra-aortic involvement.
Imaging and anatomic stratification
Imaging defines the anatomic territory and pathologic mechanism (atherosclerotic, dissecting, or inflammatory) to determine the appropriate evidence pathway .
For vertebral disease, imaging differentiates extracranial origin lesions from intracranial stenosis. Extracranial disease falls under extracranial cerebrovascular guidance, whereas intracranial vertebrobasilar disease carries distinct and prohibitive procedural risks .
For subclavian disease, interpretation links the anatomic lesion to the specific clinical syndrome being investigated (arm claudication or steal physiology) . For brachiocephalic disease, imaging assesses the full supra-aortic territory at risk to ensure cerebral and upper-extremity ischemia are evaluated independently of standard carotid stenosis criteria .
For cervical dissection, imaging confirms the diagnosis and classifies the lesion as extracranial ischemic, intracranial nonhemorrhagic, or intracranial with hemorrhage to direct antithrombotic therapy . For inflammatory conditions, imaging confirms large-vessel vasculitis and sequences systemic immunosuppression prior to revascularization .
Medical therapy and secondary prevention
Medical therapy is the default management strategy for atherosclerotic vertebral, subclavian, and brachiocephalic disease. Baseline secondary prevention includes antiplatelet therapy, blood-pressure control, statin therapy, and lifestyle intervention . Intensive antithrombotic strategies are informed by trial data for the broader stable atherosclerotic population rather than lesion-specific mandates .
For acute symptomatic extracranial cervical artery dissection, antithrombotic therapy (antiplatelet or anticoagulant) is selected based on dissection location, ischemic mechanism, and bleeding risk . Large-vessel vasculitis requires a primary immunosuppression strategy governed by a rheumatologic framework before revascularization is considered .
Procedural intervention and repair thresholds
Intervention for uncommon supra-aortic and cervical arterial disease is reserved for specific clinical syndromes refractory to medical management, rather than absolute angiographic stenosis percentages.
Decision logic for intervention follows a stepwise anatomic evaluation:
- Determine the territory and classify the underlying pathology (atherosclerotic, dissecting, or inflammatory).
- Manage systemic inflammatory disease (vasculitis) and acute dissections medically.
- For asymptomatic atherosclerotic lesions, continue medical therapy and surveillance.
- For symptomatic subclavian or brachiocephalic disease, relieve the documented syndrome (claudication or steal): angioplasty and stenting for a focal stenosis, and open reconstruction (carotid-subclavian bypass or subclavian-carotid transposition; transthoracic endarterectomy or aorto-innominate bypass for innominate disease) for occlusive, ostial, or endovascular-refractory lesions.
- For symptomatic extracranial vertebral disease, consider intervention only after medical therapy fails.
- Exclude symptomatic intracranial stenosis from procedural intervention due to established harm.
- Clinical presentation or anatomy
- Asymptomatic, or initial symptomatic presentation
- Preferred management pathway
- Medical therapy
Citation- Clinical presentation or anatomy
- Symptomatic posterior-circulation ischemia refractory to medical therapy
- Preferred management pathway
- Selective stenting consideration
CitationIntracranial vertebral artery
- Clinical presentation or anatomy
- Symptomatic intracranial stenosis
- Preferred management pathway
- Medical therapy; stenting contraindicated
CitationSubclavian artery
- Clinical presentation or anatomy
- Asymptomatic
- Preferred management pathway
- Observation and medical therapy
CitationSubclavian artery
- Clinical presentation or anatomy
- Arm claudication, coronary-subclavian steal, or vertebrobasilar steal
- Preferred management pathway
- Angioplasty and stenting for a focal stenosis; carotid-subclavian bypass or subclavian-carotid transposition for occlusive, ostial, or refractory disease
CitationBrachiocephalic artery
- Clinical presentation or anatomy
- Cerebral or upper-extremity ischemia
- Preferred management pathway
- Endovascular stenting, or open transthoracic endarterectomy or aorto-innominate bypass for occlusive or ostial disease
CitationCervical artery dissection
- Clinical presentation or anatomy
- Acute symptomatic extracranial dissection
- Preferred management pathway
- Antiplatelet or anticoagulant therapy
CitationLarge-vessel vasculitis
- Clinical presentation or anatomy
- Systemic inflammatory disease with cervical involvement
- Preferred management pathway
- Systemic immunosuppression before revascularization
Citation
Follow-up tracks the specific failure mode of the treated syndrome: recurrent posterior-circulation ischemia for vertebral disease, recurrent claudication or steal symptoms for subclavian disease, and individualized ischemia assessments for brachiocephalic disease .
Areas of controversy
The efficacy of vertebral stenting for stroke prevention remains unsupported by robust randomized data. Trials (VAST) and meta-analyses demonstrate no clear superiority of extracranial vertebral stenting over medical therapy, leaving intervention thresholds qualitative and center-dependent . Intracranial stenting is definitively contraindicated; the SAMMPRIS trial was halted early for harm, and VISSIT was stopped for futility and harm .
The choice between antiplatelet and anticoagulant therapy for acute symptomatic extracranial cervical artery dissection remains at clinical equipoise. The CADISS trial found a low 12-month ipsilateral stroke rate (2.4%) with no statistically significant difference between the two strategies; notably, every recurrent stroke occurred in a patient whose initial presentation was stroke rather than local symptoms alone (neck pain, headache, or Horner syndrome), marking the stroke-presenting subgroup as the higher-risk group who warrant the most aggressive antithrombotic decisions. TREAT-CAD reinforced the need for individualized selection rather than dogmatic protocol .
High-quality comparative evidence for carotid revascularization cannot be extrapolated to vertebral, subclavian, or brachiocephalic lesions. Endarterectomy and stenting trial data (ICSS, EVA-3S, ACT-1, ACST-2, ROADSTER, ROADSTER 2, and the SVS VQI TCAR Surveillance Project) apply strictly to carotid bifurcation disease and do not justify intervention in other supra-aortic distributions .
References
- 1.2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). 2017.PubMed-indexed articleClinical practice guideline2017
2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). 2017. doi:10.1093/eurheartj/ehx095.
- 2.2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease: Executive Summary. 2011.PubMed-indexed articleClinical practice guideline2011
2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease: Executive Summary. 2011. doi:10.1161/str.0b013e3182112d08.
- 3.Society for Vascular Surgery clinical practice guidelines for management of extracranial cerebrovascular disease.PubMed-indexed articleClinical practice guideline2021
Society for Vascular Surgery clinical practice guidelines for management of extracranial cerebrovascular disease. doi:10.1016/j.jvs.2021.04.073.
- 4.Editor's Choice – European Society for Vascular Surgery (ESVS) 2023 Clinical Practice Guidelines on the Management of Atherosclerotic Carotid and Vertebral Artery Disease. 2023.PubMed-indexed articleClinical practice guideline2023
Editor's Choice – European Society for Vascular Surgery (ESVS) 2023 Clinical Practice Guidelines on the Management of Atherosclerotic Carotid and Vertebral Artery Disease. 2023. doi:10.1016/j.ejvs.2022.04.011.
- 5.
- 6.Effect of a Balloon-Expandable Intracranial Stent vs Medical Therapy on Risk of Stroke in Patients With Symptomatic Intracranial Stenosis. 2015.PubMed-indexed articleRandomized controlled trial2015
Effect of a Balloon-Expandable Intracranial Stent vs Medical Therapy on Risk of Stroke in Patients With Symptomatic Intracranial Stenosis. 2015. doi:10.1001/jama.2015.1693.
- 7.
- 8.
- 9.
- 10.2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis. 2021.PubMed-indexed articleClinical practice guideline2021
2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis. 2021. doi:10.1002/art.41774.
- 11.2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. 2021.PubMed-indexed articleClinical practice guideline2021
2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. 2021. doi:10.1161/str.0000000000000375.
- 12.
- 13.
- 14.Stenting for symptomatic vertebral artery stenosis: a preplanned pooled individual patient data analysis (Lancet Neurology, 2019).PubMed-indexed articleMeta-analysis / systematic review2019
Stenting for symptomatic vertebral artery stenosis: a preplanned pooled individual patient data analysis (Lancet Neurology, 2019). doi:10.1016/S1474-4422(19)30149-8.
- 15.Stenting versus medical treatment in patients with symptomatic vertebral artery stenosis: a randomised open-label phase 2 trial. 2015.PubMed-indexed articleRandomized controlled trial2015
Stenting versus medical treatment in patients with symptomatic vertebral artery stenosis: a randomised open-label phase 2 trial. 2015. doi:10.1016/s1474-4422(15)00017-4.
- 16.CADISS Final Results - Antiplatelet vs Anticoagulation for Cervical Artery Dissection (Markus, JAMA Neurology 2019).PubMed-indexed articleRandomized controlled trial2019
CADISS Final Results - Antiplatelet vs Anticoagulation for Cervical Artery Dissection (Markus, JAMA Neurology 2019). doi:10.1001/jamaneurol.2019.0072.
- 17.
- 18.
- 19.
- 20.
- 21.
- 22.
- 23.
- 24.
Educational use only
AI assists this editorial workflow. Published updates are human-reviewed before publication.
Not intended to diagnose, monitor, predict, prognose, treat, or alleviate disease.
Verify clinically relevant information against primary sources and current guidelines.